GlaxoSmithKline plc (GSK) to Issue Dividend of GBX 19
GlaxoSmithKline plc (LON:GSK) declared a dividend on Wednesday, October 25th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, November 9th will be paid a dividend of GBX 19 ($0.25) per share on Thursday, January 11th. This represents a yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th. The official announcement can be seen at this link.
Shares of GlaxoSmithKline plc (LON GSK) traded up GBX 9.50 ($0.13) on Friday, reaching GBX 1,361 ($17.96). 7,047,222 shares of the company’s stock traded hands.
GlaxoSmithKline plc (LON:GSK) last released its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%. The business had revenue of GBX 784.30 billion during the quarter.
A number of research analysts recently issued reports on the company. J P Morgan Chase & Co restated a “neutral” rating and set a GBX 1,570 ($20.72) price objective on shares of GlaxoSmithKline plc in a research report on Monday, October 2nd. Liberum Capital reiterated a “buy” rating and set a GBX 1,760 ($23.23) price target on shares of GlaxoSmithKline plc in a research report on Wednesday, October 25th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.07) price target on GlaxoSmithKline plc and gave the stock a “buy” rating in a research report on Wednesday, July 26th. BNP Paribas set a GBX 1,620 ($21.38) price target on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research report on Wednesday, September 6th. Finally, Beaufort Securities reiterated a “buy” rating and set a GBX 1,800 ($23.75) price target on shares of GlaxoSmithKline plc in a research report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have given a buy rating to the company’s stock. GlaxoSmithKline plc has an average rating of “Hold” and an average target price of GBX 1,619.75 ($21.37).
In related news, insider Simon Dingemans bought 1,076 shares of the business’s stock in a transaction dated Thursday, October 12th. The shares were bought at an average cost of GBX 1,527 ($20.15) per share, with a total value of £16,430.52 ($21,681.87). Also, insider Urs Rohner bought 473 shares of the business’s stock in a transaction dated Wednesday, October 25th. The shares were bought at an average cost of GBX 1,518 ($20.03) per share, for a total transaction of £7,180.14 ($9,474.98). Insiders have bought 1,574 shares of company stock worth $2,398,888 over the last ninety days.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.